Goal to end AIDS by 2030 'more off-track' after Trump cuts, UNAIDS head says
JOHANNESBURG, June 13 (Reuters) - Donald Trump's cuts to HIV/AIDS programmes will further derail an already faltering plan to end the disease as a public health threat by 2030, UNAIDS Executive Director Winnie Byanyima said on Friday.
With 1.3 million new infections in 2023, according to the latest data, the world was already "off track," Byanyima told journalists in South Africa, a country with the world's largest number of people living with HIV, at 8 million.
"Less funding means we will get more and more off-track," she said in the main city of Johannesburg, after meeting President Cyril Ramaphosa to discuss Africa's HIV/AIDS strategy in light of the U.S. president slashing billions of dollars in foreign aid in February.
"We don't know yet what that impact will be, but impact there will be: ... already you see in several countries a drop in the number of people going to clinics," Byanyima said.
Before the cuts, prevention programmes had brought down new infections, she said, but they were "not coming down fast enough to reach our target of 2023."
Now, with the shuttering of community prevention clinics across Africa, infections would surely rise, though it wasn't clear yet by how much, she said.
The administration's decision to axe swaths of U.S. foreign aid has disrupted the supply of life-saving HIV treatments, with some countries facing potentially running out. In South Africa, about a fifth of whose HIV budget was U.S.-funded, testing and monitoring of HIV patients is already falling.
Byanyima said even poor, indebted countries were managing to plug funding gaps, but called on other rich nations to step in.
"We're saying to the donors: this is one of the diseases ... without a cure, without a vaccine, yet we're seeing progress," she said. "If you've got a good success story, why drop it ... before you end it?"
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Telegraph
34 minutes ago
- Telegraph
NHS boss claims Nigerian mother got the ‘black service'
An NHS boss has claimed his Nigerian mother received the 'black service, not an NHS service' after dying from suspected lung cancer. Lord Victor Adebowale, chairman of the NHS Confederation, which represents all health organisations, said the death of his 92-year-old mother was 'undignified'. His mother Grace, who worked as an NHS nurse for 45 years, died in January, possibly from lung cancer, but it was not detected until after she died. Lord Victor said there were 'too many situations where people that look like me and shades of me don't get the service'. 'It was not the dignified death that we would have wanted for her. It wasn't the death she deserved,' he told the NHS ConfedExpo conference in Manchester. 'So it makes me clear about the need to address the inequity. I think she got a black service, not an NHS service.' Mrs Adebowale emigrated from Nigeria to Scotland in the 1950s and worked as a nurse across mental health, maternity and acute care, during her career. Lord Victor, who grew up in Wakefield, said that he did not want to blame anyone for her death as the details were not yet clear, but he said that he wanted to highlight a 'systematic problem'. 'She lived to the age of 92 and you may think, 'well, she had a good old innings', but for a lot of those years she was in some discomfort, and it looks like she died from cancer,' he said. 'It's still the case that if you look like me, you're more likely to discover that you've got cancer in A&E, and that for me is an example of two different services.' 'Black people have worse outcomes' He added: 'I used the phrase 'black service'... you only have to look at the stats – across all the major disease categories that we talk about, black people have a worse experience and worse outcomes – we've known that for years, I'm not saying anything new.' He said his mother was an example of a wider issue and he was 'sick of it not changing like everyone else, and I'm close enough to it to know that it happens'. He said there was nothing in his mother's medical records to suggest she had cancer, and that she had gone to A&E in 'poor condition' at a hospital that 'was really struggling when she went in'. Lord Victor said his sister had to argue for their mother to be given a room but that they had not found the reason for her death yet. 'We haven't got to the bottom of it, and that's why I'm not blaming anybody, and I don't want to, but I can talk about my experience and my observation of what happened to my mum,' he said. 'How does that happen? I know it does happen. People have chronic diseases and people don't know and they die of them – I know it's more likely to happen if you're black, it's also more likely to happen if you're poor.' Of his mother, whose full name was Grace Amoke Owuren Adebowale, and who worked in various nursing sectors including mental health, acute care and maternity, he said: 'If you are a nurse, it is what you are, it's what you're born to do.' He went on: 'It is not acceptable that someone who looks like me, on average waits 20 minutes longer in A&E than white patients.' Kate Seymour, head of external affairs at Macmillan Cancer Support, said the story highlighted 'the heartbreaking reality for some when it comes to accessing cancer care in this country'. 'It is categorically unacceptable that some people with cancer are having worse experiences simply because of who they are or where they live. The Government in England has a unique opportunity in its upcoming cancer plan to revolutionise cancer care,' she said. An NHS spokesperson said: 'Everyone – no matter their background – should receive the best NHS care possible. 'That's why we are working across the NHS to ensure that happens – from improving access to cancer diagnosis and treatment, to expanding health checks for Black and Asian communities and increasing uptake of blood pressure and cholesterol medication in under-served groups. 'But we know there is much more to do, and tackling health inequalities will form an important part of the upcoming 10 Year Health Plan.'
Medical News Today
36 minutes ago
- Medical News Today
Celiac disease: Is an easier way to diagnose it on the horizon?
Could a blood test diagnose celiac disease without the need to trigger symptoms? Image credit: Alvaro Lavin/Stocksy. Celiac disease has to do with an abnormal immune response of the body to gluten. Experts are interested in the best ways to test for celiac disease. A recent study discovered that a blood test called WBAIL-2 could aid in diagnosing celiac disease and even contribute to biopsy-free diagnosis. Celiac disease occurs when someone's immune system responds abnormally to gluten. Efforts to improve celiac disease diagnosis are ongoing. A study recently published in Gastroenterology evaluated the effectiveness of using a blood test that measures the cytokine interleukin-2 to diagnose celiac disease. The study's results indicated that the test to be highly effective for celiac disease diagnosis, even for people following a gluten-free diet. The test could offer another option to help with celiac disease diagnosis — importantly, one that would not require triggering symptoms to confirm the disease. The authors of the current study note that there is often a delay or lack of diagnosis when it comes to celiac disease. Diagnosis usually involves people having to eat gluten and get biopsies of the small intestine. Celiac disease also has to do with the response of a group of immune cells, CD4+ gluten-specific T-cells. For this study, researchers wanted to determine if the use of a blood test that measures interleukin-2 — a protein produced by some T-cells — release could help to accurately diagnose celiac disease. This research involved a total of 181 adult participants between 18 and 75 years old. Of these participants, 88 had celiac disease, and others were controls. Among controls, 32 participants had a non-celiac gluten sensitivity and were on a gluten-free diet. The rest were healthy controls who did not have gluten sensitivity. All participants provided blood samples, and researchers collected data on medications and medical history. A subset of participants, including healthy controls, participants with non-celiac gluten sensitivity, and treated celiac disease, went on a gluten-free diet for four weeks or more and then consumed gluten for 'a single-dose open-label gluten challenge.' Some participants with treated celiac disease also did an oral gluten challenge that lasted 3 days. If participants underwent the oral gluten challenge, they used diaries to keep track of their symptoms. Researchers utilized a blood test called a WBAIL-2 assay, which measures the release of interleukin-2 in vitro after adding gluten peptides. In general, the test was able to effectively confirm celiac disease, with higher concentrations and fold change of interleukin-2 in participants who had celiac disease. However, the results were less sensitive for participants with a certain, less common genotype. Analysis results also found that the WBAIL-2 assay correlated with age and the number of years participants had been following a gluten-free diet. Next, researchers tested participants' serum levels of interleukin-2 after they did an oral gluten challenge. The levels of interleukin-2 were higher for participants with celiac disease following the oral gluten challenge. Researchers also found these levels 'positively correlated with the WBAIL-2 results.' So, if the levels of interleukin-2 were elevated on one test, they were also elevated on the other. They also tested how the WBAIL-2 results related to the presence of gluten-specific T cells, which were higher among participants with celiac disease. They did find that the presence of these cells, as well as activated versions of these cells, correlated with the WBAIL-2 test. The researchers further found that gluten-specific T cells, activated versions of these cells, and WBAIL-2 increased after participants underwent a gluten challenge. However, one participant had lower gluten-specific CD4+ T cells and a lower WBAIL-2 test on day six. Researchers also looked at treated celiac disease participants and how the tests related to their symptoms after gluten exposure. When it came to gluten-specific T-cells, their frequency was higher in participants who experienced vomiting. The measurement of serum interleukin-2 following the gluten tolerance test was also elevated, as was the WBAIL-2 level. The WBAIL-2 level was also increased greatly for one participant who did not experience vomiting but did report severe tiredness. Further analysis also suggested that activated gluten-specific CD4+ T cells are the cells that lead to gluten-induced production of interleukin-2. The results suggest that the WBAIL-2 assay can help with celiac disease diagnosis, even when people are already following a gluten-free diet. There are some limitations to this study. For one thing, it was performed out of one area, most participants were female, and there were strict inclusion criteria, so it has a limited generalizability. It also had small sample sizes for some subgroups, which means more research may be particularly necessary in these subgroups. Since researchers did not test children or people taking immunosuppressants, more research is needed to see how well this testing method would work in these populations. Researchers also acknowledge an untested 'reproducibility across laboratories.' More research is thus needed before the WBAIL-2 assay can really be used in the clinical setting. Further, the authors did not examine the cost-effectiveness of the WBAIL-2 test and how well this would stack up against current ways of diagnosing celiac disease. Then, the test was not as accurate for some participants with a specific genotype, which means it might not work for everyone. However, the number of participants with this genotype was very small in this study, and it is possible that the level of interleukin-2 response of some participants with this genotype was just not able to be detected by the test. Overall, more research is required regarding this subtype of individuals and the use of this test. Ian Storch, DO, an osteopathic physician specializing in gastroenterology and internal medicine, and an American Osteopathic Association member, who was not involved in this study, spoke to Medical News Today about its findings. 'One limitation of this study is the poor performance in the DQ8 genetic arm, which makes up 10% of celiac patients. This will decrease the sensitivity and specificity for the control group or require HLA typing before the assay is run.' Researchers acknowledge that the serum analysis of interleukin-2 following a gluten challenge does not always line up with the results of the WBAIL-2 assay, which could have to do with the assays' differences. Shilpa Mehra Dang, MD, double board-certified in gastroenterology and internal medicine with Medical Offices of Manhattan and contributor to LabFinder, who was similarly not involved in this research, noted that 'we need to look at bigger samples to really see its clinical usefulness.' In addition to larger studies, research can also focus on more details regarding gluten-specific T cells. Celiac disease is a challenging condition to manage, and accurate diagnosis is important. Researchers suggest that examining WBAIL-2 and serum interleukin-2 after gluten consumption could allow people with celiac disease to not have to get biopsies done to confirm celiac diagnosis. The authors of this study also suggest that the WBAIL-2 assay could also become a first test among people following a gluten-free diet and help with symptom severity prediction. Storch said: 'I do not think that based on the data presented, removal of histology to confirm the diagnosis can be suggested.' Jeffrey D. Davis, DO, CMD, an osteopathic physician specializing in Family Medicine and Preventive Health and an American Osteopathic Association board member, who was not involved in the study, noted the following to MNT : 'I see potential for a commercially available rapid, simple, cost-effective laboratory test for physicians to use to assist in the accurate diagnosis of celiac disease. This study shows that especially in adults already on a gluten-free diet using this lab test versus currently available tests would improve our diagnostic capabilities for Celiac Disease. However, it would most likely be just another tool in our tool box to aid in the diagnosis along with other current diagnostic methods.'
Metro
6 hours ago
- Metro
Urgent recall for vitamin gummies over 'life-threatening health risk'
Vitamin gummies have been recalled across the US because they may contain an undeclared allergen – peanuts. Vita Warehouse Corp is recalling a lot of its Welby brand Vitamin B12 Energy Support gummy product 1000 mcg gummies, Berkely Jensen Vitamin B12 1000 mcg Gummies, and VitaGlobe Vitamin B12 Extra Strength Gummies. 'People with an allergy or severe sensitivity to peanuts run the potential risk of serious or life-threatening allergic reactions if they consume these products,' states an advisory published by the US Food and Drug Administration (FDA) on Friday. The Webly vitamins came with 140 gummies in a clear bottle with a white cap and a green, red and white label. They have an expiration date of October 2026, the UPC code 4099100290868 and the lot number 248046601 printed at the bottom. Berkley Jensen vitamins under the recall came with 250 gummies in a clear bottle with a white cap and red and pink labels. They have an expiration date of October 2026, the UPC code 888670132487 and the lot number 248046601. The VitaGlobe vitamins came with 60 gummies in a clear bottle with a white cap and green, red and white labels. They have the same expiration date as the other two brands, the UPC code 850005214670 and the lot number 248046601. They were sent to ALDI and BJ's stores nationwide. There have not been any allergic reactions or illnesses linked to the vitamins that have been reported. More Trending Anyone who experiences an allergic reaction should see a doctor right away. Customers who are allergic to peanuts should throw them away immediately or return them for a full refund. 'Vita Warehouse Corp is committed to maintaining the highest product safety and quality standards,' states the FDA notice. It comes a week after Aldi recalled its Casa Mamita Churro Bites Filled with Chocolate Hazelnut Cream because they were found to have an undeclared allergen, milk, that could cause 'a serious or life-threatening allergic reaction'. Get in touch with our news team by emailing us at webnews@ For more stories like this, check our news page. MORE: Man 'urinates on $10,000 worth of Spam and sausages forcing them to be tossed' MORE: Everything to know about Donald Trump's military parade on his 79th birthday MORE: Lawmaker forcefully removed from Trump secretary's LA protests conference and handcuffed
